Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Windtree Therapeutics stock (WINT)

Buy Windtree Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Windtree Therapeutics is a biotechnology business based in the US. Windtree Therapeutics shares (WINT) are listed on the NASDAQ and all prices are listed in US Dollars.

Our top picks for where to buy Windtree Therapeutics stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Windtree Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – WINT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Windtree Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 3.1 / 5: ★★★★★
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Windtree Therapeutics stock price (NASDAQ: WINT)

Use our graph to track the performance of WINT stocks over time.

Windtree Therapeutics shares at a glance

Information last updated 2024-07-22.
Latest market close$3.56
52-week range$2.89 - $30.06
50-day moving average $3.60
200-day moving average $9.52
Wall St. target price$7.00
PE ratio 0.2712
Dividend yield N/A (0%)
Earnings per share (TTM) $13.31

Is it a good time to buy Windtree Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Windtree Therapeutics price performance over time

Historical closes compared with the close of $3.56 from 2024-07-22

1 week (2024-07-16) -4.04%
1 month (2024-06-21) 13.38%
3 months (2024-04-23) -37.36%
6 months (2024-01-23) 666.42%
1 year (2023-07-21) 156.12%
2 years (2022-07-22) 774.91%
3 years (2021-07-23) 94.54%
5 years (2019-07-23) 12.45

Is Windtree Therapeutics stock undervalued or overvalued?

Valuing Windtree Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Windtree Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Windtree Therapeutics's P/E ratio

Windtree Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Windtree Therapeutics shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Windtree Therapeutics financials

Gross profit TTM $-17,787,000
Return on assets TTM -33.58%
Return on equity TTM -53.1%
Profit margin 0%
Book value $30.23
Market Capitalization $2.1 million

TTM: trailing 12 months

Windtree Therapeutics share dividends

We're not expecting Windtree Therapeutics to pay a dividend over the next 12 months.

Have Windtree Therapeutics's shares ever split?

Windtree Therapeutics's shares were split on a 1:18 basis on 21 April 2024. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Windtree Therapeutics shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for Windtree Therapeutics shares which in turn could have impacted Windtree Therapeutics's share price.

Windtree Therapeutics share price volatility

Over the last 12 months, Windtree Therapeutics's shares have ranged in value from as little as $2.89 up to $30.06. A popular way to gauge a stock's volatility is its "beta".

WINT.US volatility(beta: 0.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Windtree Therapeutics's is 0.561. This would suggest that Windtree Therapeutics's shares are less volatile than average (for this exchange).

Windtree Therapeutics overview

Windtree Therapeutics, Inc. , a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr.

Frequently asked questions

What percentage of Windtree Therapeutics is owned by insiders or institutions?
Currently 4.013% of Windtree Therapeutics shares are held by insiders and 9.215% by institutions.
When does the fiscal year end for Windtree Therapeutics?
Windtree Therapeutics's fiscal year ends in December.
Where is Windtree Therapeutics based?
Windtree Therapeutics's address is: 2600 Kelly Road, Warrington, PA, United States, 18976-3622
What is Windtree Therapeutics's ISIN number?
Windtree Therapeutics's international securities identification number is: US97382D3035
What is Windtree Therapeutics's CUSIP number?
Windtree Therapeutics's Committee on Uniform Securities Identification Procedures number is: 97382D303

More guides on Finder

Ask a question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site